A near-infrared fluorescent probe and its preparation method and application

By developing the near-infrared fluorescence probe RBN, the fluorescence emission characteristics after reaction with ONOO- was solved, and the safety and sensitivity in the diagnosis of necrotic enterocolitis in neonatal is achieved and high sensitivity detection of ONOO- and Early diagnosis provides a safe and fast auxiliary screening method.

CN118515681BActive Publication Date: 2024-11-12XUZHOU MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410601903.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-15
Publication Date
2024-11-12
Estimated Expiration
2044-05-15

AI Technical Summary

Technical Problem

The prior art has problems with low safety, sensitivity and specificity in the diagnosis of necrotic enterocolitis in premature neonatal neonatal neonatal, and X-ray imaging has radiation risks to the human body, and a safe, fast and reliable auxiliary screening is urgently needed. method.

Method used

A near-infrared fluorescence probe RBN was developed to open the helical ring structure after reacting with ONOO- to achieve fluorescence emission, used to detect ONOO- and provide a diagnostic method for necrotic enterocolitis in neonatal infants, by Test the sample and inject the probe and detect the fluorescence intensity to determine the risk of disease.

Benefits of technology

It improves the detection sensitivity and response speed of ONOO-, realizes real-time detection of ONOO-, can achieve stable value within 60s, has high sensitivity and specificity, and is suitable for early diagnosis and monitoring of necrotic enterocolitis in neonatal infants. Simple to operate, low cost, and is not affected by other disturbing analytes in complex environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118515681B_ABST
    Figure CN118515681B_ABST
Patent Text Reader

Abstract

The present invention discloses a novel near-infrared fluorescent probe and a preparation method and application thereof. The structural formula of the probe is as follows: #imgabs0# When ONOO ‑ When present, the fluorescence emission peak of the probe is at 668 nm. This small molecule fluorescent probe greatly improves the detection of ONOO ‑ The detection sensitivity of the near-infrared fluorescent probe is improved, which reduces the detection limit. ‑ The response speed is fast and it can basically reach a stable value within 60s, which can realize ONOO ‑ Real-time visual detection, and has good anti-interference ability. The present invention proposes ONOO ‑ The concentration of ONOO is closely related to the development of neonatal necrotizing enterocolitis, and the severity of intestinal damage can also be judged from the relative intensity of fluorescence. ‑ This study has great potential and also provides a new option for the early diagnosis and monitoring of neonatal necrotizing enterocolitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection technology, and in particular to a near-infrared fluorescent probe and a preparation method and application thereof. Background Art

[0002] Necrotizing enterocolitis (NEC) is a common and fatal digestive tract disease in premature newborns (especially very low birth weight infants), with a mortality rate of 15% to 30%. Once NEC develops, it progresses very rapidly, and is prone to serious life-threatening conditions such as intestinal necrosis and perforation. Therefore, early diagnosis and treatment are the key to improving the clinical efficacy and prognosis of NEC.

[0003] Common diagnostic methods for necrotizing enterocolitis (NEC) include blood tests, stool tests, and X-rays. However, the first two methods can only check bacterial information and do not have the specificity to determine the type of disease. X-ray imaging is of great value in diagnosing the disease because it detects characteristic imaging changes such as intestinal wall and portal vein gas accumulation, but it has low sensitivity. When these typical manifestations appear, the disease has already progressed to NEC stage II-III. When the imaging manifestations are atypical, it is easy to miss or misdiagnose. More importantly, X-ray imaging has a certain amount of radiation to the human body, which may cause irreversible damage to newborns. Therefore, in clinical practice, there is an urgent need for safe, fast and reliable methods to assist in screening NEC and determine the severity of intestinal damage.

[0004] As a visual detection tool, the fluorescent probe method has the advantages of high sensitivity, good selectivity, simple operation, real-time monitoring and no damage to biological samples. Therefore, it is widely used in many fields such as chemistry, biology, and medicine. The near-infrared wavelength range is mainly between 650 and 900 nm. Compared with most traditional ultraviolet and visible light, near-infrared light has stronger penetration, less energy and no destructiveness. Reactive oxygen species (ROS) (including hydroxyl radicals, singlet oxygen, nitric oxide, hydrogen peroxide, superoxide, etc.) play a vital role in various life processes. There is a lot of evidence that excessive reactive oxygen species can damage host tissues, cause DNA damage and many diseases. For example, it has been reported in the literature that reactive oxygen free radicals are overexpressed in necrotizing enterocolitis. Therefore, in order to better understand the role of ROS in various diseases, we must develop efficient and sensitive probes to sense the changes in various ROS levels in biological systems, and detection and analysis based on fluorescent probes is one of the very effective methods. Summary of the invention

[0005] In view of the deficiencies of the above-mentioned prior art, the technical problems to be solved by the present invention are: to provide a near-infrared fluorescent probe and a preparation method thereof, thereby enriching the types and selectivity of the existing fluorescent probes; the present invention also provides an application method of the fluorescent probe in the detection of neonatal necrotizing enterocolitis, thereby solving the problems of low safety, sensitivity and specificity of the existing detection methods.

[0006] In order to solve the above technical problems, the present invention adopts the following technical solution: a near-infrared fluorescent probe, the structural formula of the probe is as follows: When ONOO - When present, the probe has an ultraviolet absorption peak at 578 nm and a fluorescence emission peak at 668 nm.

[0007] Another object of the present invention is to provide a method for preparing the above-mentioned near-infrared fluorescent probe, and its synthesis route is as follows:

[0008]

[0009] The method comprises the following steps: dissolving compound 7 and NH2NH2.H2O in an organic solvent, adding a coupling reagent, and then stirring the reaction solution at 25°C for reaction. After the reaction is completed, the obtained solution is subjected to reduced pressure distillation to remove CH2Cl2, and the blue solid obtained after column chromatography separation is the near-infrared fluorescent probe RBN.

[0010] Preferably, the molar ratio of compound 7 to NH2NH2.H2O is 1:1 to 1:4.

[0011] Preferably, the coupling reagent is BOP reagent, DCC reagent or HBTU reagent; the concentration ratio of the coupling reagent to compound 7 in the reaction solution is 1:8 to 1:14.

[0012] Preferably, the reaction time is 3 h to 8 h.

[0013] Preferably, the eluent in the column chromatography is dichloromethane / methanol, and the volume ratio of dichloromethane to methanol is 8:1 to 30:1.

[0014] Another object of the present invention is to provide the above-mentioned near-infrared fluorescent probe for detecting ONOO - Application in this area.

[0015] Another object of the present invention is to provide the use of the above-mentioned near-infrared fluorescent probe in the preparation of a diagnostic product for neonatal necrotizing enterocolitis.

[0016] Another object of the present invention is to provide a diagnostic drug comprising the above-mentioned near-infrared fluorescent probe, wherein the diagnostic drug is- Diagnostic products for abnormal related diseases. Preferably, the disease includes neonatal necrotizing enterocolitis. Specifically, the judgment standard of the diagnostic drug for neonatal necrotizing enterocolitis is: inject 20 μM of the near-infrared fluorescent probe RBN into the sample to be tested intraperitoneally, and detect its fluorescence intensity at 668 nm, with the fluorescence intensity generated by the healthy sample as the control. When the relative fluorescence intensity of the test sample is more than twice that of the control, there is a risk of necrotizing enterocolitis; if not, there is no risk of necrotizing enterocolitis.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] 1. The present invention provides a near-infrared fluorescent probe RBN, in which the side carboxyl group of the rhodamine substituent is modified by the amino nitrogen atom in hydrazine hydrate to form an amide group. The amide group forms a five-membered spiro ring with the carbon atom, interrupting the conjugated structure of the compound. - When the compound is present, fluorescence quenching occurs; - After the reaction, the hydrazide group undergoes oxidation reaction by opening the spiro ring and restoring the compound conjugated system, so that its fluorescence emission has a significant red shift at 668nm, thereby generating fluorescence and triggering a "switch" effect. In addition, the rigid structure of the five-membered ring suppresses intramolecular vibration and increases the fluorescence quantum yield. This design greatly improves the ONOO - The detection sensitivity of the near-infrared fluorescent probe is improved, which reduces the detection limit. - The response speed is fast and it can basically reach a stable value within 60s, which can realize ONOO - Real-time detection of RBN probes and ONOO - Form an efficient and innovative fluorescence response mechanism.

[0019] 2. The present invention provides a method for diagnosing neonatal necrotizing enterocolitis using RBN probe, and proposes ONOO - The concentration of ONOO is closely related to the development of neonatal necrotizing enterocolitis, which will help us better understand the cause of neonatal necrotizing enterocolitis. The severity of intestinal damage can also be judged from the relative intensity of fluorescence, and early treatment intervention measures can be taken for neonatal necrotizing enterocolitis. Therefore, the RBN probe has the potential to detect ONOO in biological systems. - The method has great potential for early diagnosis and monitoring of enterocolitis and provides a new option for early diagnosis and monitoring of enterocolitis. - 、NO、H2O2、O2 - 、NO2 -, I2 and TBHP have no fluorescence response and have good anti-interference ability, so that the presence of other interfering analytes in a complex environment will not affect its effect on ONOO - The specificity and recognition performance of the protein have good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 It is the mass spectrum and carbon spectrum of the RBN probe of the present invention.

[0021] Figure 2 is the in vitro optical response of the RBN probe of the present invention; a is the ultraviolet absorption peak, and b is the fluorescence emission peak.

[0022] Figure 3 This is a sensitivity test of the RBN probe of the present invention; a is a curve diagram of fluorescence intensity changes in response to different concentrations of NO; ​​b is a standard curve diagram.

[0023] Figure 4 This is a response test of the RBN probe of the present invention.

[0024] Figure 5 This is a specificity test of the RBN probe of the present invention.

[0025] Figure 6 This is the detection of cell toxicity by the RBN probe of the present invention.

[0026] Figure 7 The RBN probe of the present invention is used to detect neonatal necrotizing enterocolitis; A is a schematic diagram of the experimental process, B is the fluorescence detection of different groups of mice, C is the relative fluorescence intensity of different groups of mice, and D is the stained sections of the small intestine of different groups of mice.

[0027] Figure 8 This is a schematic diagram of the principle of using the RBN probe of the present invention to detect neonatal necrotizing enterocolitis. DETAILED DESCRIPTION

[0028] The present invention is further described in detail below in conjunction with the examples. The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0029] 1. Preparation method of near-infrared fluorescent probe

[0030] Example

[0031] A preparation process route of a near-infrared fluorescent probe is as follows:

[0032] Compound 7 (270 mg, 0.2 mmol) and NH2NH2.H2O (0.1 mL) were dissolved in an organic solvent, and then BOP reagent (221 mg, 2 mmol) was added to obtain a reaction solution. The reaction solution was stirred at 25°C for 3 hours. After the reaction, the product was filtered to remove the solid, and the obtained solution was distilled under reduced pressure to remove CH2Cl2. Then, column chromatography was performed by silica gel column chromatography (CH2Cl2 / MeOH=14:1, v / v) to obtain a blue solid, which was the target probe RBN (62 mg, 33%).

[0033] The obtained target probe was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum. The results are as follows Figure 1 The specific data is as follows:

[0034] 1 H-NMR (400 MHz, CHLOROFORM-d) δ7.96–7.87 (m, 1H), 7.49–7.34 (m, 2H), 7.15–7.05 (m, 1H), 6.49–6.33 (m, 2H), 6.28 (dd, J=9.0, 2.6 Hz, 1H), 6.18 (s, 1H), 5.63 (d, J=7.1 Hz, 1H), 3.70–3.49 (m, 3H), 3.48–3.18 (m, 7H), 2.55 (s, 3H), 2.12–1.94 (m, 3H), 1.16 (t, J=7.1 Hz, 6H).

[0035] 13 C-NMR (101 MHz, chloroform-d) δ 153.91, 151.80, 148.74, 146.77, 137.24, 132.46, 132.17, 129.78, 127.99, 127.96, 123.91, 122.93, 107.85, 106.99, 104.31, 103.14, 97.90, 96.80, 56.80, 54.49, 53.42, 47.42, 44.35, 39.84, 30.26, 29.70, 23.58, 12.63.

[0036] In summary, the molecular formula of the probe molecule obtained by the present invention is [C 30 H 34 N5O2 + ]=496.2707, HRMS measured value MS=496.2718, the structural formula is as follows:

[0037]

[0038] 2. Near-infrared fluorescent probe molecular performance detection

[0039] 1. In vitro optical response test of fluorescent probes

[0040] Equal amounts of RBN probes were added to PBS:DMSO = 95:5 buffer solution to obtain a mixed solution, and then 100 μM ONOO was added to part of the mixed solution. - As the experimental group, 100 μM buffer solution was added to part of the mixed solution as the control group; 50 μl of the control group and the experimental group were added to a 96-well plate, and the absorption peak and fluorescence intensity were observed. The results are as follows Figure 2 shown.

[0041] from Figure 2 As can be seen in a, the probe RBN is light blue, and the UV absorption peak is at 578nm; adding ONOO - After addition, the absorption intensity of the experimental group at 578 nm increased by almost 5 times, and the color changed from light blue to red. In the fluorescence response experiment, the probe RBN - In the case of (control group), a weak emission band centered at 668 nm was shown ((Φ) = 0.03). However, when ONOO was added to the probe RBN, - After (experimental group), the quantum yield (Φ) was significantly enhanced to 0.56. In addition, strong red fluorescence was observed in the experimental group under a portable 365nm lamp. The absorption and fluorescence experimental data confirmed the effect of probe RBN on ONOO - Have the ability to identify.

[0042] 2. Sensitivity test of fluorescent probe

[0043] ONOO - The standard solution was added to a PBS:DMSO = 95:5 buffer solution to simulate the physiological environment in vivo (the same below), and different concentrations were diluted, and 50 μl was added to a 96-well plate, and then RBN probe (10 μM) was added to obtain the test solution. The final ONOO in the test solution - The concentrations of the test solution were 0 μM, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, 9 μM and 10 μM, respectively, and then the fluorescence intensity of the test solution at 668 nm was detected. The results are as follows Figure 3 shown.

[0044] from Figure 3 As can be seen in Figure a, with ONOO - As the concentration increases, the fluorescence intensity increases. From the corresponding fitting simulation curve data ( Figure 3 b) Analysis shows that ONOO - In the concentration range of 0 to 30 μM, ONOO - The increase in concentration has a good linear relationship with the fluorescence enhancement intensity.2 The value is 0.99686. Based on the calculation formula of 3σ / k (σ represents the deviation of the response value, k represents the slope of the relationship curve), the detection limit of the probe is determined to be 56nM. Therefore, the linear range of the present invention is wide, the detection sensitivity is high, and it can achieve low concentration ONOO - The detection of ONOO also shows that the probe RNB can be used as an accurate quantitative - potential as a reliable tool.

[0045] 3. Response test of near-infrared fluorescent probe

[0046] ONOO - The standard solution was added to PBS:DMSO = 95:5 buffer solution, diluted to different concentrations, and then 50 μl was added to a 96-well plate, and then RNB probe (10 μM) was added to obtain the detection solution. The final ONOO in the detection solution - The concentrations of the samples were 10 μM, 20 μM and 50 μM respectively, and then the fluorescence intensity changes at 668 nm of the samples were detected over time. The results are as follows Figure 4 shown.

[0047] from Figure 4 It can be seen that different concentrations of ONOO - After contacting with the RNB probe, the fluorescence intensity increased rapidly and reached a stable value within 60 s, indicating that the RNB probe of the present invention has a strong affinity for ONOO - The response speed is fast and the sensitivity is high, which can realize ONOO - Real-time detection.

[0048] 4. Specificity test of near-infrared fluorescent probe

[0049] ONOO - The standard solution was added into PBS:DMSO=95:5 buffer solution, and ONOO - The concentration was diluted to 10 μM, 50 μl was added to a 96-well plate, and then the RNB probe and the interfering analyte were added to obtain the detection solution, wherein the concentration of the fluorescent probe was 10 μM, the concentration of the interfering analyte was 100 μM, and the interfering analyte was OCl - 、NO、H2O2、O2 - 、NO2 - , I2 and TBHP, and then use a fluorescence spectrophotometer to detect the fluorescence intensity of each test solution at 668nm. The results are as follows Figure 5 shown.

[0050] from Figure 5 As can be seen from the figure, the probe of the present invention is similar to OCl - 、NO、H2O2、O2 -、NO2 - The fluorescence changes caused by the coexistence of ONOO, I2 and TBHP can be ignored, that is, there is no fluorescence response. - When ONOO is present, a significant enhancement of fluorescence can be observed at 668 nm, with the fluorescence increasing by more than 200 times. - It has good selectivity and can be used in complex environments without affecting the presence of other interfering analytes to ONOO - specificity and recognition performance.

[0051] 5. Cytotoxicity test of fluorescent probe

[0052] RAW264.7 cells (mouse monocyte macrophages) and HepG2 (human liver cancer cells) in logarithmic growth cycle were inoculated in 96-well plates, respectively, at 37°C and 5% CO2, and then fresh culture medium solutions (without serum) containing different concentrations (0 μM, 5 μM, 10 μM, 20 μM, 30 μM, 40 μM) of fluorescent probes were added, respectively. After incubation with the cells for 24 hours, the CCK-8 kit was used for detection according to the instructions. After the reaction was completed, the OD value was measured at 490 nm by a microplate reader, and the cell survival rate (%) was calculated. The results are shown in FIG. Figure 6 shown.

[0053] from Figure 6 It can be seen that when the near-infrared fluorescent probe is within the range of 40 μM, the survival rate of RAW264.7 and HepG2 cells is higher than 85%, and the maximum cell viability can reach 95%. The effect on the cell (survival rate) in the experiment is negligible. The results show that the RBN probe of the present invention has high biocompatibility and low toxicity, and is very suitable for biological detection applications.

[0054] 6. Near-infrared fluorescent probe for the detection of neonatal necrotizing enterocolitis

[0055] Lipopolysaccharide (LPS) and hypoxia are inflammatory mediators that induce the occurrence of necrotizing enterocolitis. Several healthy newborn mice were selected and evenly divided into 3 groups. The untreated mice were used as the control group. One group of mice was treated with hypoxia 3 times a day, artificially fed 20 minutes after hypoxia, and intraperitoneally injected with LPS once. The intervention was continued for 3 days to obtain necrotizing enterocolitis model mice as the disease group. Another group of mice was treated with hypoxia 3 times a day, artificially fed 20 minutes after hypoxia, and intraperitoneally injected with LPS once. At the same time, they received UA treatment once a day as the treatment group. The specific operations are as follows: Figure 7 A. Then, 20 μM RNB probe was intraperitoneally injected into the mice in the disease group, treatment group, and control group, and the fluorescence intensity and its changes at 668 nm were observed. The results are shown in Figure 7 As shown in B.

[0056] from Figure 7 As shown in Figure B, no obvious fluorescence was observed in the control group, while the diseased group showed obvious fluorescence in the abdomen, while other organs showed slight fluorescence. This is because the side carboxyl group of the rhodamine substituent in the RNB probe is modified by the amino nitrogen atom in hydrazine hydrate to form an amide group. The amide group forms a five-membered spiro ring with the carbon atom, interrupting the conjugated structure of the compound. - When the compound is present, fluorescence quenching occurs; - After the reaction, the hydrazide group undergoes oxidation reaction by opening the spiro ring and restoring the conjugated system of the compound, causing its fluorescence emission to have an obvious red shift at 668nm, thereby generating fluorescence and inducing a "switch" effect ( Figure 7 ), thus indicating that ONOO in the intestinal region - Compared with the diseased group, the fluorescence observed in the UA-treated group was much weaker, indicating that ONOO - The level of TNF-α decreased, and the condition of necrotizing enterocolitis was restored to a certain extent. This finding was also strengthened by the relative fluorescence intensity. Compared with the control group, the fluorescence intensity of the abdomen in the UA treatment group and the diseased group increased significantly ( Figure 7 (C), the relative fluorescence intensity of the UA-treated group and the diseased group was approximately 3 and 5 times that of the control group.

[0057] At the same time, the colons of mice in the disease group, treatment group, and control group were stained with hematoxylin and eosin (H&E). Figure 7 As shown in D. Compared with the control group, the colon of the diseased group showed pathological changes of varying degrees of hair loss, dysfunction, lack of intestinal glands, thinning of the muscular layer, and even rupture. In the UA-treated group, the loss of small intestinal villi was observed, but compared with the diseased group, the necrosis had recovered to a certain extent, and the muscular layer was intact without rupture. It can be seen that the colon pathology of mice is consistent with the detection results of the near-infrared fluorescent probe RBN of the present invention. The severity of intestinal damage can be judged from the relative intensity of fluorescence with a high accuracy. Therefore, the near-infrared fluorescent probe RBN has the potential to become a monitoring tool for ONOO in deep tissues and living organisms. - A powerful tool for level changes.

[0058] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A near-infrared fluorescent probe, It is characterized in that The structural formula of the probe is as follows: When ONOO - When present, the probe has a peak fluorescence emission at 668 nm.

2. A method for preparing the near-infrared fluorescent probe as claimed in claim 1, It is characterized in that Its synthetic route is as follows: The following steps are involved: Compound 7 is reacted with NH 2 NH 2· H 2 O was dissolved in an organic solvent, dichloromethane, and then a coupling reagent was added. The reaction solution was stirred at 25°C. After the reaction was completed, the obtained solution was distilled under reduced pressure to remove CH 2 Cl 2 , and then the blue solid obtained after column chromatography separation is the near-infrared fluorescent probe RBN.

3. The method for preparing the near-infrared fluorescent probe according to claim 2, It is characterized in that The compound 7 and NH 2 NH 2 .H 2 The molar ratio of O is 1:1 to 1:

4.

4. The method for preparing the near-infrared fluorescent probe according to claim 2, It is characterized in that The coupling reagent is a BOP reagent, a DCC reagent or a HBTU reagent.

5. The method for preparing the near-infrared fluorescent probe according to claim 2, It is characterized in that The reaction time is 3h to 8h.

6. The method for preparing the near-infrared fluorescent probe according to claim 2, It is characterized in that The eluent in the column chromatography is dichloromethane / methanol, and the volume ratio of dichloromethane to methanol is 8:1 to 30:

1.

7. Use of the near-infrared fluorescent probe according to claim 1 in preparing a diagnostic product for neonatal necrotizing enterocolitis.

8. A diagnostic drug, It is characterized in that It comprises the near-infrared fluorescent probe according to claim 1, wherein the diagnostic drug is ONOO - Diagnostic products for abnormality-related diseases.

9. The diagnostic drug according to claim 8, It is characterized in that The disease is neonatal necrotizing enterocolitis.